C4 Therapeutics (CCCC) Equity Average: 2019-2025
Historic Equity Average for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $164.2 million.
- C4 Therapeutics' Equity Average fell 32.93% to $164.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.2 million, marking a year-over-year decrease of 32.93%. This contributed to the annual value of $231.1 million for FY2024, which is 13.68% down from last year.
- Latest data reveals that C4 Therapeutics reported Equity Average of $164.2 million as of Q3 2025, which was down 11.03% from $184.6 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Equity Average registered a high of $407.6 million during Q3 2021, and its lowest value of $164.2 million during Q3 2025.
- In the last 3 years, C4 Therapeutics' Equity Average had a median value of $231.1 million in 2023 and averaged $228.5 million.
- In the last 5 years, C4 Therapeutics' Equity Average spiked by 531.38% in 2021 and then slumped by 32.93% in 2025.
- Quarterly analysis of 5 years shows C4 Therapeutics' Equity Average stood at $394.2 million in 2021, then declined by 22.95% to $303.7 million in 2022, then declined by 23.92% to $231.1 million in 2023, then decreased by 0.76% to $229.3 million in 2024, then crashed by 32.93% to $164.2 million in 2025.
- Its Equity Average stands at $164.2 million for Q3 2025, versus $184.6 million for Q2 2025 and $205.6 million for Q1 2025.